CSL Ltd

Price Chart

Risk-Adjusted Performance

CSL Ltd (CSL) Price Performance

CSL Ltd (CSL) trades on Australian Securities Exchange in AUD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at AUD140.81, up 1.02% from the previous close.

Over the past year, CSL has traded between a low of AUD138.00 and a high of AUD268.88. The stock has lost 44.2% over this period. It is currently 48.2% below its 52-week high.

CSL Ltd has a market capitalization of $66.95B, with a price-to-earnings ratio of 15.66 and a dividend yield of 2.07%.

About CSL Ltd

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.